Robert Kilkuskie

Director/Miembro de la Junta en Michigan High Throughput Screening Center .

Commercial Services

Perfil

Robert Kilkuskie currently works at Michigan High Throughput Screening Center, as Executive Director from 2009 and National Institute of Health Policy, as Principal.

Cargos activos de Robert Kilkuskie

Empresas	Cargo	Inicio
Michigan High Throughput Screening Center Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties.	Director/Miembro de la Junta	-
National Institute of Health Policy	Corporate Officer/Principal	30/04/2010

Todos los cargos activos de Robert Kilkuskie

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Robert Kilkuskie.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Michigan High Throughput Screening Center Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties.	Commercial Services
National Institute of Health Policy